BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 17261547)

  • 1. The role of mannose receptor during experimental leishmaniasis.
    Akilov OE; Kasuboski RE; Carter CR; McDowell MA
    J Leukoc Biol; 2007 May; 81(5):1188-96. PubMed ID: 17261547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
    Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
    Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mice lacking the TNF receptor p55 fail to resolve lesions caused by infection with Leishmania major, but control parasite replication.
    Vieira LQ; Goldschmidt M; Nashleanas M; Pfeffer K; Mak T; Scott P
    J Immunol; 1996 Jul; 157(2):827-35. PubMed ID: 8752935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.
    Satoskar AR; Rodig S; Telford SR; Satoskar AA; Ghosh SK; von Lichtenberg F; David JR
    Eur J Immunol; 2000 Mar; 30(3):834-9. PubMed ID: 10741399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice.
    Sato N; Kuziel WA; Melby PC; Reddick RL; Kostecki V; Zhao W; Maeda N; Ahuja SK; Ahuja SS
    J Immunol; 1999 Nov; 163(10):5519-25. PubMed ID: 10553079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leishmania-induced cellular recruitment during the early inflammatory response: modulation of proinflammatory mediators.
    Matte C; Olivier M
    J Infect Dis; 2002 Mar; 185(5):673-81. PubMed ID: 11865425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cells augment lesion size and persistence during experimental Leishmania major infection in the mouse.
    Wershil BK; Theodos CM; Galli SJ; Titus RG
    J Immunol; 1994 May; 152(9):4563-71. PubMed ID: 8157970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern recognition and renal defence in crescentic glomerulonephritis.
    Berger SP; Daha MR
    Nephrol Dial Transplant; 2010 Sep; 25(9):2876-8. PubMed ID: 20650906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis.
    Liese J; Schleicher U; Bogdan C
    Eur J Immunol; 2007 Dec; 37(12):3424-34. PubMed ID: 18034422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?
    McMahon-Pratt D; Alexander J
    Immunol Rev; 2004 Oct; 201():206-24. PubMed ID: 15361243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR-mediated distinct IFN-γ/IL-10 pattern induces protective immunity against murine visceral leishmaniasis.
    Paul J; Karmakar S; De T
    Eur J Immunol; 2012 Aug; 42(8):2087-99. PubMed ID: 22622993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
    Murray HW; Moreira AL; Lu CM; DeVecchio JL; Matsuhashi M; Ma X; Heinzel FP
    J Infect Dis; 2003 Aug; 188(3):458-64. PubMed ID: 12870129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs.
    Schleicher U; Liese J; Knippertz I; Kurzmann C; Hesse A; Heit A; Fischer JA; Weiss S; Kalinke U; Kunz S; Bogdan C
    J Exp Med; 2007 Apr; 204(4):893-906. PubMed ID: 17389237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mannose receptor (MR) and Toll-like receptor 2 (TLR2) influence phagosome maturation during Leishmania infection.
    Polando RE; Jones BC; Ricardo C; Whitcomb J; Ballhorn W; McDowell MA
    Parasite Immunol; 2018 Apr; 40(4):e12521. PubMed ID: 29512160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 1alpha activity of peritoneal and bone marrow macrophages infected with Leishmania major and Leishmania donovani in vitro.
    Bersudsky M; Apte RN; El-On J
    Exp Parasitol; 2000 Mar; 94(3):150-7. PubMed ID: 10831379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
    Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines, signaling pathways, and effector molecules required for the control of Leishmania (Viannia) braziliensis in mice.
    Rocha FJ; Schleicher U; Mattner J; Alber G; Bogdan C
    Infect Immun; 2007 Aug; 75(8):3823-32. PubMed ID: 17517868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology.
    Rosas LE; Satoskar AA; Roth KM; Keiser TL; Barbi J; Hunter C; de Sauvage FJ; Satoskar AR
    Am J Pathol; 2006 Jan; 168(1):158-69. PubMed ID: 16400019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.